+
“Building companies and technologies that enhance the fundamental systems of human health and aging.”
BRAHM Life Sciences operates at the intersection of longevity science, biotechnology, and traditional medical systems.
Our mission is to develop and commercialize health technologies that enhance the biological systems underlying human vitality and aging.
Both modern longevity biology and traditional medical systems such as Ayurveda share a systems-level view of health — recognizing that long-term wellbeing depends on the regulation of metabolism, immune resilience, tissue regeneration, and physiological balance rather than the treatment of isolated symptoms.
BRAHM focuses on translating this systems-based understanding of health into measurable, scalable biomedical innovation.
BRAHM Life Sciences operates as a venture creation and research commercialization platform.
We work with scientists, entrepreneurs, and research institutions to transform promising scientific discoveries into scalable companies and health technologies.
Our role is to bridge three critical domains:
● Scientific discovery
● Strategic capital
● Global healthcare markets
By connecting these elements, we help breakthrough research move from laboratory insight to real-world healthcare solutions.
BRAHM works with innovators across biotechnology, longevity science, and translational medicine to:
● Identify high-potential scientific discoveries
● Support venture creation and company formation
● Build partnerships between global researchers and India’s life sciences ecosystem
● Accelerate the development of scalable health technologies
● Translate complex scientific insights into clinically measurable interventions
Our approach combines scientific collaboration, venture building, and long-term strategic capital.
BRAHM Life Sciences focuses on technologies that enhance the core biological systems that sustain human health and influence aging.
These include:
● Metabolic and mitochondrial resilience
● Immune regulation and inflammatory control
● Tissue regeneration and cellular repair
● Microbiome and metabolic signaling
● Precision diagnostics and AI-driven health data
● Translational research integrating traditional medical systems with modern biomedical science
Rather than focusing on individual diseases, our approach emphasizes optimizing the biological systems that maintain health across the lifespan.
BRAHM believes the future of medicine will emerge from the convergence of multiple medical paradigms.
Modern longevity science provides deep mechanistic insights into aging biology, while traditional medical systems such as Ayurveda offer centuries of observational knowledge centered on systemic health regulation.
By combining modern biotechnology, clinical data, and systems biology with these broader medical frameworks, BRAHM seeks to develop new categories of preventative and longevity-focused health technologies.
This approach enables us to both:
● Translate global advances in aging biology into scalable healthcare solutions
● Bring insights from traditional medical systems into modern biomedical research
BRAHM Life Sciences collaborates with scientists, entrepreneurs, and investors across India, Europe, the Middle East, and Asia-Pacific.
India represents one of the most important emerging ecosystems for the future of global health innovation — combining:
● World-class scientific talent
● Large and diverse patient populations
● Advanced pharmaceutical manufacturing capacity
● Deep traditions in medical knowledge
By connecting global research with India’s life sciences ecosystem, BRAHM aims to accelerate the development and adoption of new health technologies.
At the core of BRAHM Life Sciences is the conviction that longevity will define the next era of medicine.
Through its partnership with Iduna Capital, a venture fund focused on the biology of aging, BRAHM invests in companies developing technologies that target the biological drivers of aging and age-related disease.
These include innovations addressing:
● Cellular senescence
● Immune system decline
● Metabolic dysfunction
● Regenerative capacity
● Chronic inflammation
By connecting global scientific innovation with India’s scale, research infrastructure, and clinical ecosystem, the partnership between BRAHM Life Sciences and Iduna Capital seeks to accelerate the development of longevity-focused therapies and health technologies.
Iduna Capital is a venture capital fund dedicated to investing in biotechnology companies advancing the science of aging and longevity.
The fund focuses on early-stage companies developing therapies that target the biological mechanisms underlying age-related disease and physiological decline.
Areas of focus include:
● Cellular health and senescence biology
● Immune system resilience
● Metabolic and mitochondrial function
● Regenerative medicine and tissue repair
● Precision diagnostics and aging biomarkers
With a projected $50M fund, Iduna Capital partners with scientists, founders, and research institutions to support the development of regulated therapies that extend healthy human lifespan.
For most of human history, aging was viewed as an inevitable process of decline.
Advances in modern biology increasingly suggest that aging is a complex biological process driven by identifiable mechanisms that can be studied and potentially influenced.
Researchers have identified several biological processes that contribute to aging, including:
● Chronic inflammation
● Cellular senescence
● DNA damage accumulation
● Mitochondrial dysfunction
● Stem cell exhaustion
By targeting these underlying mechanisms, scientists aim to extend healthspan — the number of years people live in good health — rather than simply prolonging life.
Emerging technologies such as AI-driven drug discovery, gene editing, cellular reprogramming, and precision diagnostics are rapidly expanding our ability to understand and intervene in aging biology.
BRAHM Life Sciences and Iduna Capital support companies developing these technologies to advance the next generation of healthcare.
Beiersdorf and Vincere Biosciences Partner to Bring Mitophagy to Market.
Why Lifespan Heritability Is Twice as High as We Thought
Billions of lab-grown mitochondria, real-world regeneration, & a vision for future medicine.
-Peter Højer Mathiesen
Director of Life Sciences, Brahm
© 2025 Brahm. All rights reserved.
Brahm is a registered entity. All content, visuals, and materials are protected by applicable intellectual property laws.